Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Cytophage Technologies Ltd.

Healthcare CA CYTO

0.005CAD
0.00(0%)

Last update at 2026-06-19T13:30:00Z

Day Range

0.0050.005
LowHigh

52 Week Range

0.030.40
LowHigh

Fundamentals

  • Previous Close 0.005
  • Market Cap4.06M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.29570M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.86270M -4.63542M -0.70621M -3.23517M
Minority interest - - - -
Net income -7.86270M -4.63542M -0.70621M -3.23517M
Selling general administrative 4.30M 3.89M 0.71M 2.85M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.71M 0.51M 0.36M 0.30M
Ebit - - - -
Ebitda - - - -
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -5.15419M -4.59403M -0.79224M -3.20464M
Other operating expenses - - - -
Interest expense 0.10M 0.03M 0.02M 0.03M
Tax provision - - - -
Interest income 0.14M 0.00379M 0.09M -
Net interest income 0.04M -0.03047M 0.09M -0.03053M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 5.15M 4.59M 0.79M 3.20M
Cost of revenue - - - -
Total other income expense net -2.74846M -0.01091M -0.04187M -
Discontinued operations - - - -
Net income from continuing ops -7.86270M -4.63542M -0.70621M -3.23517M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4.94M 5.44M 3.69M 5.83M
Intangible assets - - - -
Earning assets - - - -
Other current assets - - - -
Total liab 2.01M 5.07M 0.24M 0.28M
Total stockholder equity 2.93M 0.37M 3.45M 5.55M
Deferred long term liab - - - -
Other current liab - 2.50M - -
Common stock - - - -
Capital stock 25.28M 16.18M 15.44M 14.31M
Retained earnings -26.56249M -19.08986M -14.45445M -10.77205M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 1.52M 0.03M 2.25M 4.84M
Cash and equivalents - - - -
Total current liabilities 0.68M 3.64M 0.24M 0.17M
Current deferred revenue - - - -
Net debt - - - -
Short term debt - - - -
Short long term debt - 0.03M - -
Short long term debt total - - - -
Other stockholder equity - - - -
Property plant equipment - - - -
Total current assets 1.82M 2.95M 2.75M 4.96M
Long term investments - - - -
Net tangible assets - - - -
Short term investments - 5.43M - -
Net receivables 0.00000M 0.26M 0.00442M 0.00000M
Long term debt - - - -
Inventory - - - -
Accounts payable 0.21M 0.36M 0.11M 0.01M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 3.11M 2.49M 0.94M 0.87M
Capital lease obligations 1.54M 1.77M 0.11M 0.26M
Long term debt total - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.05754M -4.52500M -
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings -0.03620M -0.18646M -0.14786M -0.13062M
Total cash from financing activities -0.05995M 3.26M 4.41M 6.58M
Change to operating activities - - - -
Net income -7.86270M -4.63542M -0.70621M -3.23517M
Change in cash 1.49M -2.21466M -0.11761M 3.22M
Begin period cash flow 0.03M 2.25M 0.19M 1.62M
End period cash flow 1.52M 0.03M 0.07M 4.84M
Total cash from operating activities -4.76972M -2.85841M -0.04647M -3.03210M
Issuance of capital stock 0.00000M 0.52M 5.00M 6.59M
Depreciation 0.71M 0.51M 0.36M 0.30M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables 0.25M -0.14972M -0.11442M 0.00000M
Sale purchase of stock - - - -
Other cashflows from financing activities - - - -
Change to netincome - - - -
Capital expenditures 1.30M 0.16M 0.38M 0.33M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -0.30431M 0.43M -0.07287M -0.14699M
Stock based compensation 0.00000M 0.82M 0.67M 0.05M
Other non cash items 2.69M 0.01M 0.07M 0.00100M
Free cash flow -6.07450M -3.02050M -0.04647M -3.36517M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
CYTO
Cytophage Technologies Ltd.		 - -% 0.005 - - - 3.48
SHRX
Sharp Therapeutics Corp.		 - -% 1.00 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01 1.79% 0.55 - 6.90 - 15.26 -7.2365
MIR
MedMira Inc		 - -% 0.07 - - 223.37 - 293.42 -80.0318
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.56 - - - 15.17 -58.1577

Reports Covered

Stock Research & News

View All

Profile

Cytophage Technologies Ltd., a biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. It develops poultry health products under the AviPhage name; food safety products under the PhageFend name; bovine mastitis products under the BoviPhage name; and water-soluble solution for livestock producers under the FarmPhage name. The company is headquartered in Oak Bluff, Canada.

Cytophage Technologies Ltd.

400 Fort Whyte Way, Oak Bluff, MB, Canada, R4G 0B1

Key Executives

Name Title Year Born
Dr. Steven Theriault B.Sc., M.Sc., Ph.D. CEO, Chief Science Officer & Director NA
Mr. Julius John Kalcevich M.B.A. Chief Financial Officer 1975
Ms. Heather Medwick B.A. Chief Operating Officer NA
Mr. Michael Graham M.B.A. Chief Commercialization Officer 1977
Mr. James F. Kinley C.A., CPA Chief Financial Officer 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.